Edition:
United States

Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

17.30USD
18 Aug 2017
Change (% chg)

$0.20 (+1.17%)
Prev Close
$17.10
Open
$17.10
Day's High
$17.53
Day's Low
$17.10
Volume
1,985,632
Avg. Vol
2,311,924
52-wk High
$53.96
52-wk Low
$16.81

Summary

Name Age Since Current Position

Sol Barer

70 2017 Chairman of the Board

Yitzhak Peterburg

66 2017 Interim President and Chief Executive Officer

Eyal Desheh

65 2014 Group Executive Vice President, Chief Financial Officer

Dipankar Bhattacharjee

56 2016 President and Chief Executive Officer-Global Generic Medicines Group

Carlo de Notaristefani

59 2012 President and Chief Executive Officer-Global Operations

Robert Koremans

55 2013 President, Chief Executive Officer - Global Specialty Medicines

Iris Beck-Codner

51 2014 Group Executive Vice President - Corporate Marketing & Communication

Hafrun Fridriksdottir

55 2017 Executive Vice President, President of Global Generics R&D

Mark Sabag

46 2013 Group Executive Vice President-Human Resources

David Stark

48 2016 Group Executive Vice President-Chief Legal Officer

Timothy Wright

59 2015 Executive Vice President, Business Development, Strategy and Commercial Innovation

Michael Hayden

65 2012 President - Global Research and Development, Chief Scientific Officer

Roger Abravanel

71 2007 Director

Rosemary Crane

57 2015 Director

Amir Elstein

61 2014 Director

Gerald Lieberman

70 2015 Director

Galia Maor

74 2012 Director

Ory Slonim

74 2008 Director

Jean-Michel Halfon

65 2014 Statutory-Independent Director

Joseph Nitzani

71 2008 Statutory Independent Director

Gabrielle Sulzberger

56 2015 Statutory Independent Director

Kevin Mannix

Senior Vice President, Head of Investor Relations

Biographies

Name Description

Sol Barer

Dr. Sol J. Barer serves as Chairman of the Board at Teva Pharmaceutical Industries Limited since February 6, 2017. Until this date, he served as Director at the Company from January 1, 2015. He serves as Chairman of the Science and Technology committee and as Vice Chairman of the CSR Responsibility committee. His work experience includes the following roles: Managing Partner at SJ Barer Consulting, has held top leadership roles at Celgene Corporation (1987-2011) including Executive Chairman (2010-2011), Chairman and Chief Executive Officer (2007-2010), Chief Executive Officer (2006-2010), President and Chief Operating Officer (1994-2006) and President (1993-1994), Founder of the biotechnology group at the chemical company Celanese Corporation (which was later spun off as Celgene), Director at Amicus Therapeutics and Aegerion Pharmaceuticals and Chairman of the Board of InspireMD and Medgenics. Dr. Barer holds a Bachelor of Science degree in Chemistry from City University of New York at Brooklyn College and a Doctorate of Science degree in Organic and Physical Chemistry from Rutgers, The State University of New Jersey.

Yitzhak Peterburg

Dr. Yitzhak Peterburg serves as Interim President and Chief Executive Officer at Teva Pharmaceutical Industries Limited since February 6, 2017. Until this date, he served as Chairman of the Board at the Company from January 1, 2015. His work experience includes the following roles: Director at the Company (January 2012-January 1, 2015; 2009-July 2010), Group Vice President-Global Branded Products at the Company (October 2010-October 2011), President and Chief Executive Officer at Cellcom Israel Ltd. (2003-2005), Director General of Clalit Health Services (1997-2002), Chief Executive Officer at Soroka University Medical Center (1995-1997), Director at Rosetta Genomics Ltd. and Chairman at Regenera Pharma Ltd. Dr. Peterburg holds a Doctorate of Medicine degree from Hadassah Medical School and is board-certified in Pediatrics and Health Services Management. He also holds a Doctorate in Philosophy degree in Health Administration from Columbia University and a Master of Science degree in Information Systems from London School of Economics. He is a Professor at the School of Business of Ben-Gurion University.

Eyal Desheh

Mr. Eyal Desheh serves as Group Executive Vice President and Chief Financial Officer at Teva Pharmaceutical Industries Limited since 2012. On April 26, 2017, an official announcement stated that he will depart from the Company in the coming months. A further official announcement will follow in due course with the precise date. His work experience includes the following roles: Chief Financial Officer at the Company (since July 2008), Interim President and Chief Executive Officer (October 30, 2013-February 11, 2014), Executive Vice President and Chief Financial Officer at Check Point Software Technologies Ltd (2000-2008), Chief Financial Officer at Scitex Ltd (1996-2000) and Deputy Chief Financial Officer at the Company (1989-1996). He holds a Bachelors degree in Economics and a MBA degree, majoring in Finance, both from The Hebrew University of Jerusalem.

Dipankar Bhattacharjee

Mr. Dipankar Bhattacharjee serves as President and Chief Executive Officer-Global Generic Medicines Group of Teva Pharmaceutical Industries Limited since December 5, 2016. His work experience includes the following roles: President and Chief Executive Officer-Generics Europe at the Company (April 2013-2016), Chief Executive Officer-Teva UK Limited (2009-2013) and Senior Vice President, Western Europe; Vice President-Commercial, Europe at Bausch + Lomb, Vice President-Commercial, Asia Pacific at Bausch + Lomb, Corporate Vice President and President, Asia Pacific at Bausch + Lomb, Employee at Nestlé SA and Employee at Bank of America. He holds a Bachelor of Arts degree in Economics from St. Stephens College, University of Delhi and a Masters degree in Management Studies from Jamnalal Bajaj Institute of Management Studies, University of Mumbai.

Carlo de Notaristefani

Dr. Carlo de Notaristefani serves as President and Chief Executive Officer-Global Operations at Teva Pharmaceutical Industries Limited since 2012. His work experience includes the following roles: Member of the Senior Management team at Bristol-Myers Squibb, where he served as President Technical Operations and Global Support Functions, with responsibility for global supply chain operations, quality and compliance, procurement and information technology (2004-2011) and holder of Senior positions involving global operations and supply chain management at Aventis, Hoechst Marion Roussell and Marion Merrell Dow. Dr. de Notaristefani holds a Doctorate of Science degree in Chemical Engineering from University of Naples.

Robert Koremans

Dr. Robert (Rob) Koremans serves as President and Chief Executive Officer - Global Specialty Medicines at Teva Pharmaceutical Industries Limited since 2013. Prior to this role, he served as President and Chief Executive Officer at Teva Pharmaceuticals Europe from March 2012. His work experience includes the following roles: Member of the Global Leadership Team of Sanofi, Chief Executive Officer at Zentiva, Senior Vice President Generics, Strategy and Development at Sanofi, Chief Executive Officer at Cryo-Save, Member of the Executive Board in charge of Global Commercial Operations at Grunenthal GmbH and Vice President Europe, Middle-East and Africa at Serono. Dr. Koremans holds a Doctorate of Medicine degree from Erasmus University of Rotterdam.

Iris Beck-Codner

Ms. Iris Beck-Codner serves as Group Executive Vice President - Corporate Marketing and Communication at Teva Pharmaceutical Industries Limited since 2014. Prior to this role, she served as Senior Vice President and Chief Communications Officer at the Company (2013-2014). Her work experience includes the following roles: Group Chief Executive Officer of McCann Erickson Israel, IPG (2009-2012), Vice President Marketing and Content at Partner Communications Company Ltd (2002-2008) and General Manager at Lever Israel (a wholly-owned subsidiary of Unilever Israel; 1999-2000). She holds a Bachelor of Arts degree in Economic Sciences from Haifa University and a MBA degree from Bar-Ilan University.

Hafrun Fridriksdottir

Dr. Hafrun Fridriksdottir serves as Executive Vice President, President of Global Generics R&D at Teva Pharmaceutical Industries Limited since February 2017. Prior to this role, she served as Senior Vice President and President of Global Generics R&D at the Company from 2016. Her work experience includes the following roles: Senior Vice President and President of Global Generics R&D at Allergan Plc (2015-2016), Senior Vice President-R&D at Actavis Group (where she has worked for 13 years, including other positions) and Divisional Manager of Development at Omega Pharma (1997-2002; until it merged with Actavis). Dr. Fridriksdottir holds a Master of Science degree in Pharmacy and a Doctorate of Science degree in Physical Pharmacy from the University of Iceland.

Mark Sabag

Mr. Mark Sabag serves as Group Executive Vice President-Human Resources at Teva Pharmaceutical Industries Limited since August 2013. His work experience at the Company includes the following roles: Global Deputy Vice President-Human Resources (2012-2013), Vice President-Human Resources at Teva’s International Group (2010-2012) and Vice President-Human Resources International Group and Corporate Human Capital (2006-2010). Prior to joining Teva, he held Senior Human Resources Roles at Intel Corporation. Mr. Sabag holds a Bachelors degree in Economics and Business Management from Haifa University.

David Stark

Mr. David M. Stark serves as Group Executive Vice President-Chief Legal Officer at Teva Pharmaceutical Industries Limited since November 8, 2016. His work experience includes the following roles: Senior Vice President, General Counsel-Global Specialty Medicines (2014-2015), Senior Director, Deputy General Counsel, and Vice President and General Counsel at Teva North America and Teva Americas, Associate Attorney in the litigation departments at Willkie Farr & Gallagher LLP (1998-2002), Chadbourne & Parke (1997-1998) and Haight, Gardner, Poor & Havens (1994-1997). He holds a Bachelor of Arts degree in Political Science from Northeastern University and a Juris Doctor degree from New York University School of Law.

Timothy Wright

Mr. Timothy (Tim) R. Wright serves as Executive Vice President, Business Development, Strategy and Commercial Innovation at Teva Pharmaceutical Industries Limited since April 13, 2015. His work experience includes the following roles: Founder and Chairman of the Drug Discovery and Development Institute for The Ohio State University Comprehensive Cancer Center and a Director there (2011-2015), Member of the Ohio State Innovation Foundation Board and the Ohio State School of Pharmacy External Advisory Board, President at Covidien Pharmaceuticals (2007-2010), Interim Chief Executive Officer, President, Member of the Board of Directors and Chief Operating Officer at AAI Pharmaceuticals/Xanodyne (2004-2007), President-Global Operations at Elan Bio-Pharmaceuticals (2001-2004), President-Europe, Japan & ROW and Executive Vice President-Business Development & Licensing at Elan Bio-Pharmaceuticals (2001-2002), Senior Vice President, Strategy & Corporate Business Development at DuPont Merck Pharmaceutical Company (1996-1999), Vice President, Strategic Marketing & Operations-Europe at DuPont Merck Pharmaceutical Company (1995-1996), President and Chief Executive Officer, Toronto at DuPont Merck Pharmaceutical Company (1993-1995) and Vice President-Marketing at DuPont Merck Pharmaceutical Company (1990-1993). Mr. Wright holds a Bachelor of Science degree from Ohio State University.

Michael Hayden

Dr. Michael R. Hayden serves as President - Global Research and Development and Chief Scientific Officer at Teva Pharmaceutical Industries Limited since May 8, 2012. His work experience includes the following roles: Killam Professor of Medical Genetics at the University of British Columbia, Canada Research Chair in Human Genetics and Molecular Medicine, Founder and Senior Scientist of the Centre for Molecular Medicine and Therapeutics at the University of British Columbia, Founder of three biotechnology companies (NeuroVir, Aspreva Pharmaceuticals and Xenon Pharmaceuticals Inc.), Chief Scientific Officer at Xenon (2000-2012) and Director at Med Biogene Inc. (2010-2011). He has received numerous awards, including the Canada Gairdner Wightman Award in 2011, the Order of Canada Award in 2010 (the highest honor that Canada can give its citizens for exceptional achievement) and the Distinguished Scientist Award of the Canadian Society of Clinical Investigation in 1998 and he was named Canada’s Health Researcher of the Year in 2008. Dr. Hayden received a MB ChB in Medicine (a Bachelor of Medicine, Bachelor of Surgery degree) in 1975, a Doctorate of Science degree in Genetics in 1979 and a Diploma in Child Health (DCH) in 1979 from the University of Cape Town. He received his American Board Certification in both Internal Medicine and Clinical Genetics from Harvard Medical School in 1982 and a Fellow of the Royal College of Physicians of Canada (FRCPC) in Internal Medicine from University of British Columbia in 1984.

Roger Abravanel

Mr. Roger Abravanel serves as Director at Teva Pharmaceutical Industries Limited since January 2007. He is a member of the Human Resources, Compensation, Corporate Governance, Nominating, Finance and Investment committees. His work experience includes the following roles: Principal at McKinsey & Company (which he joined in 1972), Director at McKinsey & Company, Provider of Consulting services to Israeli and Italian private and venture capital funds, Director of COFIDE—Gruppo De Benedetti SpA (2008-2013), Director at Luxottica Group SpA (2006-2014), Director at Admiral Group plc, Director at Banca Nazionale del Lavoro (a subsidiary of BNP Paribas) and Chairman of INSEAD’s Advisory Group in Italy. Mr. Abravanel holds a Bachelor of Science degree in Chemical Engineering from Politecnico di Milano and a MBA degree from INSEAD.

Rosemary Crane

Ms. Rosemary A. Crane serves as Director at Teva Pharmaceutical Industries Limited since September 2015. She is a member of the Science, Technology and Corporate Responsibility committees. Her work experience includes the following roles: President and Chief Executive Officer of MELA Sciences, Inc. (2013-2014), Head of Commercialization and Partner at Appletree Partners (2011-2013), President and Chief Executive Officer of Epocrates Inc. (2008-2011), Group Chairman, OTC & Nutritional Group at Johnson & Johnson (2006-2008), Group Chairman, Consumer, Specialty Pharmaceuticals and Nutritionals at Johnson & Johnson (2004-2006), Executive Vice President of Global Marketing for the Pharmaceutical Group at Johnson & Johnson (2002-2004), President of U.S. Primary Care at Bristol-Myers Squibb (2000-2002), President of Global Marketing and Consumer Products at Bristol-Myers Squibb (1998-2000), Vice Chairman of the Board of Zealand Pharma A/S (since 2015). She holds a Bachelor of Arts degree in Communications and English from State University of New York and a MBA degree from Kent State University.

Amir Elstein

Mr. Amir Elstein serves as Director at Teva Pharmaceutical Industries Limited since January 2009. He is a member of the Science and Technology committees, Vice Chairman of the Finance and Investment committees and Chairman of the Corporate Governance and Nominating committees. His work experience includes the following roles: Vice Chairman of the Board of Directors of Teva (January 2014-July 2014), Independent Director at the Company (January 2009-January 2014), Executive Vice President - Global Pharmaceutical Resources at the Company (March 2007-January 2009), Director at the Company (1995-2004), Chairman of the Board of Tower Semiconductor Ltd., Chairman of the Board of Governors of the Jerusalem College of Engineering, Chairman of the Board of the Israel Democracy Institute, Chairman and/or as a member of the board of directors of several academic, scientific, educational, social and cultural institutions, Chairman of the Board of Directors of Israel Corporation (2010-2013) and General Manager of Intel Electronics Ltd. (subsidiary of Intel Corporation). He holds a Bachelor of Science degree in Physics and Math, a Master of Science degree in Solid State Physics and a Diploma of Senior Business Management, all from The Hebrew University of Jerusalem.

Gerald Lieberman

Mr. Gerald M. Lieberman serves as Director at Teva Pharmaceutical Industries Limited since September 2015. He is a member of the Human Resources, Compensation, Finance and Investment committees. His work experience includes the following roles: Special Advisor at Reverence Capital Partners, President and Chief Operating Officer at AllianceBernstein L.P. (2004-2009), Chief Operating Officer at AllianceBernstein L.P. (2003-2004), Executive Vice President, Finance and Operations at AllianceBernstein L.P. (2000-2003), Senior Vice President, Finance and Administration at Sanford C. Bernstein & Co., Inc. (1998-2000), held various Executive positions at Fidelity Investments and at Citicorp, Director at Forest Laboratories, LLC (2011-2014), Director at Computershare Ltd. (2010-2012) and Director at AllianceBernstein L.P. (2004-2009). He holds a Bachelor of Business Administration degree from University of Connecticut.

Galia Maor

Ms. Galia Maor serves as Director at Teva Pharmaceutical Industries Limited since 2012. She is a member of the Audit, Corporate Governance and Nominating committees and Chairwoman of the Finance and Investment committees. Her work experience includes the following roles: President and Chief Executive Officer at Bank Leumi Le Israel B.M. (May 1, 1991-April 30, 2012) and Director at Strauss Group Ltd. Additionally, she has held senior roles at the Bank of Israel. She holds a Bachelors degree in Economics and Statistics and a MBA degree, both from The Hebrew University of Jerusalem. Ms. Maor holds Honorary Doctorates from the Technion-Israel Institute of Technology, Ben Gurion University and Bar Ilan University.

Ory Slonim

Mr. Ory Slonim serves as Director at Teva Pharmaceutical Industries Limited since 2008. He is a member of the Audit committee, Vice Chairman of the Corporate Governance and Nominating committees and Chairman of the Corporate Responsibility. His work experience includes the following roles: Statutory Independent Director at the Company (1998-2003), Attorney (since 1970), Director and Chairman of the audit committee at U. Dori Group Ltd. (1993-2011), Director at Oil Refineries Ltd.(2007-2012), Vice Chairman of Harel Insurance Investments and Financial Services Ltd. (2008-2013), Vice Chairman of the Board of Migdal Insurance and Financial Holdings Ltd. (1988-2007), Chairman of the Variety Club-Israel (since 2006), Chairman of the Ethics Tribunal of the Israeli Press Council (since 1994) and Lecturer at Tel Aviv University (Lahav Plan). Mr. Slonim received the Presidential Volunteer Medal in 1992 and the Presidential Medal of Distinction in 2012. He holds a LLB degree from The Hebrew University of Jerusalem.

Jean-Michel Halfon

Mr. Jean-Michel Halfon serves as Statutory-Independent Director at Teva Pharmaceutical Industries Limited since 2014. He is a member of the Science and Technology committees, Vice Chairman of the Audit committee and Chairman of the Human Resources and Compensation committees. His work experience includes the following roles: Independent Consultant, Provider of Consulting Services to pharmaceutical, distribution, healthcare IT and R&D companies, President and General Manager of Emerging Markets at Pfizer Inc. (2008-2010) and Director of Marketing in France at Merck & Co. (1987-1989). Mr. Halfon holds a Bachelor of Science degree from Ecole Centrale des Arts et Manufactures and a MBA degree from Ecole Supérieur des Affaires (ESA).

Joseph Nitzani

Mr. Joseph (Yosi) Nitzani serves as Statutory Independent Director at Teva Pharmaceutical Industries Limited since September 2008. He is a member of the Corporate Responsibility, Finance and Investment, Corporate Governance and Nominating committees, Vice Chairman of the Human Resources and Compensation committees and Chairman of the Audit committee. His work experience includes the following roles: Chairman of Hadassah Medical Center (2008-2010), Director at Hadassah Medical Center (1996-2008), Head of the Client Assets Private Banking and Consulting Division at Mizrahi-Tefahot Bank Ltd, Managing Director of the Government Companies Authority (1991-1995), Chief Executive Officer at the Tel-Aviv Stock Exchange (1980-1991), Director in three subsidiaries of Migdal Capital Markets Group (December 2009-2013), Chairman at a subsidiary of Migdal Capital Markets Group (2010-2013), Director at the Tel-Aviv Stock Exchange and at S&P Maalot (both 2001-2007), Director at Adanim Mortgage Bank (2006-2008) and Chairman of the endowment fund and Member of the investment funds committee at Tel Aviv University (since 2012). He holds a Bachelor of Arts degree in Economics from Bar-Ilan University and a MBA degree from Tel Aviv University.

Gabrielle Sulzberger

Ms. Gabrielle Sulzberger serves as Statutory Independent Director at Teva Pharmaceutical Industries Limited since September 2015. She is a member of the Audit and Corporate Responsibility committees and Vice Chairwoman of the Human Resources and Compensation committees. Her work experience includes the following roles: General Partner and Investment Manager of Rustic Canyon/Fontis Partners, L.P. (since October 2005), Director at Whole Foods Market, Inc. (since 2003) where she chairs the audit committee, Director at Brixmor Property Group (since 2015), Director at Stage Stores, Inc. (2010-2015), Chief Financial Officer at several privately owned companies and Principal at several private equity capital funds. She holds a Bachelors degree in Urban Studies from Princeton University, a Juris Doctor degree from Harvard School of Law and a MBA degree from Harvard Business School.

Kevin Mannix